Keros Therapeutics, Inc. Appoints Charles Newton To Its Board Effective March 9, 2026, Strengthening Leadership During Key Clinical Progress For Rinvatercept (KER-065)

Keros Therapeutics, Inc. announced the appointment of Charles Newton to its Board of Directors, effective March 9, 2026. The company, which develops innovative therapies for conditions tied to dysfunctional signaling of the TGF-ß protein family, noted that this addition strengthens its leadership team during an important phase of clinical progress.

According to Jean-Jacques Bienaimé, Chair of the Board of Directors, the company is pleased to welcome Mr. Newton. He explained that Mr. Newton’s deep background in healthcare finance and capital markets, along with his long history of guiding companies through key clinical and strategic milestones, will add valuable expertise to the board. As Keros advances its pipeline and focuses on long-term growth, his perspective is expected to support disciplined implementation and value creation.

Mr. Newton shared that he is excited to join the board and contribute his experience to the next stage of development for rinvatercept (KER-065). He added that he looks forward to working with the board and senior leadership to help the company move forward with its strategic goals and continue progressing toward delivering potentially disease-modifying treatments to patients.

Mr. Newton previously served as Chief Financial Officer of Lyell Immunopharma, Inc. from February 2021 until his retirement in September 2025. Earlier in his career, he held several senior investment banking roles, including Managing Director and Co-Head of Healthcare Investment Banking in the Americas at Bank of America and at Credit Suisse, as well as Managing Director and Head of Western Region Healthcare Investment Banking at Morgan Stanley. 

He began his career as a Corporate Finance Analyst at Lehman Brothers. Currently, he serves on the boards of Novavax, Inc. and Coherus Oncology, Inc.. He also previously served on the boards of 2seventy bio, Inc., which was acquired by Bristol Myers Squibb, and Carmot Therapeutics, which was acquired by Roche. Mr. Newton holds a B.S. in Finance from Miami University and an M.B.A. from the Tuck School of Business at Dartmouth.

Along with the announcement of Mr. Newton’s appointment, Keros shared that Carl Gordon will step down from the Board of Directors, also effective March 9, 2026. Chief Executive Officer Jasbir Seehra, Ph.D., expressed appreciation for Dr. Gordon’s contributions, thanking him for his service and extending best wishes for his future endeavors.